Deoxyribonuclease I serum activity in pancreatic cancer.

Bull Cancer

Istituto di Medicina Interna (Cattedra di Malattie Apparato Digerente), Università degli Studi di Padova, Italia.

Published: July 1990

In patients with pancreatic cancer deoxyribonuclease I (DNase I) serum levels were compared with those of other known pancreatic enzymes. Serum deoxyribonuclease I, elastase 1, immunoreactive trypsin, amylase and phospholipase A2 were determined in 40 healthy controls, 28 patients with pancreatic cancer, 49 with chronic pancreatitis and 40 with extra-pancreatic diseases. The analysis of variance showed a significant difference among groups for serum DNase I values. However, none of the 3 groups of patients had a mean deoxyribonuclease I value higher than that of the healthy controls. In pancreatic cancer and chronic pancreatitis patients, increases in the 4 pancreatic enzymes values were found in percentages that were higher than those for DNase I. A significant correlation was found between DNase I and phospholipase A2, but not between DNase I and elastase 1, immunoreactive trypsin and amylase serum activities. The findings indicate that deoxyribonuclease I serum determination is an even less satisfactory index of pancreatic malignancy than the other pancreatic enzymes. Rather than expressing pancreatic damage, any variations in this enzyme appear more likely to reflect an aspecific phenomenon.

Download full-text PDF

Source

Publication Analysis

Top Keywords

pancreatic cancer
16
pancreatic enzymes
12
pancreatic
9
deoxyribonuclease serum
8
patients pancreatic
8
elastase immunoreactive
8
immunoreactive trypsin
8
trypsin amylase
8
healthy controls
8
cancer chronic
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!